Group 1 - The pharmaceutical sector is experiencing a diversified trend, shifting from a focus on innovative drugs to emerging fields such as performance reversals, brain-computer interfaces, and AI drug development [1] - Current market preferences include high-growth performance realization, medical device technological innovation, and major innovative drug products, influenced by recent half-year report disclosures and favorable policies [1] - Zhongtai Securities recommends innovative pharmaceutical companies with solid safety margins, such as Xiansheng Pharmaceutical, WuXi Biologics, and Sanofi, highlighting a preference for stocks driven by both performance realization and technological breakthroughs [1] Group 2 - Xiansheng Pharmaceutical has achieved multiple breakthroughs in its innovative pipeline this year, with two major new drugs approved for market: the insomnia drug Dali Reiseng and the ovarian cancer drug Suweisitamon [2] - The company has also entered into significant collaborations, including a maximum $10.55 billion partnership with AbbVie for SIM0500 and a $7.45 billion strategic cooperation with NextCure for SIM0505, optimizing its revenue structure [2] - UBS believes that the market has not fully reflected Xiansheng Pharmaceutical's R&D capabilities and the sales potential of its innovative drugs, with expectations for further approvals in the coming years [2]

Group 1 - The core viewpoint of the news is that the innovative insomnia drug Daridorexant (brand name: Kewico®) developed by the company in collaboration with Idorsia has been officially approved for marketing in China, enhancing patient access and supporting long-term use [1][2] - Daridorexant targets the orexin pathway in the hypothalamus, which is crucial for wakefulness, contrasting with traditional insomnia medications that act on GABA receptors to induce sedation [1] - The drug has shown significant clinical trial results, including reduced time to sleep onset and decreased wake time after sleep, with no serious adverse reactions reported during treatment [1] Group 2 - Daridorexant is the only DORA (Dual Orexin Receptor Antagonist) insomnia medication approved by the European Medicines Agency that improves daytime functioning, and it has been approved in 11 countries including the US, UK, and Japan [2] - The company entered into an exclusive licensing agreement with Idorsia for the development and commercialization of Daridorexant in the Greater China region, recognizing its market potential [2] - A supplementary agreement was reached between Idorsia and the company, involving a one-time cash payment of $50 million and adjustments to sales milestone payments and royalty rates, aimed at facilitating the commercialization of Daridorexant [2]